Perpetual Philanthropic Services

The Ramaciotti Foundations

2026 Health Investment Grants

Ramaciotti Health Investment Grants of up to $100,000 are awarded to individuals for a contribution towards the undertaking of health or medical research with the potential path to clinical application within five years. They are intended to provide enabling research support for autonomous early career investigators who are taking or have recently taken, a substantial position. Grants are awarded by Perpetual, as trustee of the Ramaciotti Foundations, on the recommendation of the Ramaciotti Scientific Advisory Committee.

Perpetual is pleased to congratulate this year's recipients.

RECIPIENT	INSTITUTION	PROJECT
Dr Jennifer Snaith *Derek Hart Memorial Award Recipient*	Victor Chang Cardiac Research Institute	Repurposing Tirzepatide to Transform Metabolic Outcomes in Type 1 Diabetes
Dr Peter Allen	Garvan Institute of Medical Research	Targeting pathogenic cell ageing states to halt idiopathic pulmonary fibrosis
Dr Fei Deng	University of New South Wales	Patient-Friendly CRISPR Test for Rapid Point-of-Care Detection of Dermatophyte Infections
Dr Deepani Fernando	The Council of the Queensland Institute of Medical Research	Development of the world's first, antibody-based, rapid diagnostic test for scabies point-of-care
Dr Ahmer Hameed	The University of Sydney	Development and optimization of a porcine model of normothermic regional perfusion (NRP) prior to transplantation
Dr Hamid Karimi-Rouzbahani	Mater Research Limited	Beyond the Diagnostic Ceiling: An Objective Quantitative Framework for Precision Epilepsy Surgery
Dr Hui-Fern Koay	The University of Melbourne	Harnessing a novel tissue immune axis to reprogram tumour immunity
Dr Miaomiao Liu	Griffith University	Unlocking the Molecular Targets of Mudjala: A Potent Indigenous Australian Analgesic
Dr Subash Thapa	Charles Sturt University	Co-designing a Telecare Triage Model for Rural Children with Neurodevelopmental and Mental Health Needs in NSW
Dr Alexander Underwood	University of New South Wales	Optimizing antigen 164 in humanised preclinical models for HCV vaccine development

Perpetual's Philanthropic Services and advice are provided by Perpetual Trustee Company Limited (PTCo), ABN 42 000 001 007, AFSL 236643. This publication has been prepared by PTCo and it may contain information contributed by third parties. It contains general information only and is not intended to provide advice or take into account personal objectives, financial situation or needs. The information is believed to be accurate at the time of compilation and is provided by PTCo in good faith. To the extent permitted by law, no liability is accepted for any loss or damage as a result of any reliance on this information. PTCo does not warrant the accuracy or completeness of any information included in this document which was contributed by a third party.

Trust is Earned

Perpetual